ILEA000338972: Gunze aims to commercialize regenerative blood vessels

Rapidus R&D hub in northern Japan

Yasunori Ogawa (L), president of printer manufacturer Seiko Epson Corp., and Atsuyoshi Koike, his counterpart of chipmaker Rapidus Corp., pose for a photo during a press conference in Chitose, Hokkaido, northern Japan, on Oct. 3, 2024. The two companies have agreed to the building of a Rapidus research and development center in Seiko Epson's plant in Chitose, with the facility expected to begin operating in April 2026.

New whaling factory ship

Hideki Tokoro, president of commercial whaling operator Kyodo Senpaku Co., meets the press in Shimonoseki, western Japan, on March 29, 2024, after Kangei Maru, the world's only whaling factory ship, was delivered to his company earlier in the day, following the retirement of its predecessor, Nisshin Maru, in November 2023.

KM Biologics begins development of vaccine for novel coronavirus

KM Biologics (Kita Ward, Kumamoto City) has started to develop a vaccine for a new coronavirus infection. At a press conference held on April 25, President Nagasato said, "Our strength lies in the fact that we have skilled technicians and facilities from our days at the Research Institute for Chemotherapy and Serotherapy (KAKETSUKEN). As a member of the Meiji Group, we will do our utmost to expand this business. The new drug will be developed jointly with the National Institute of Infectious Diseases, the Institute of Medical Science of the University of Tokyo, and the National Institute of Biomedical Innovation, Health and Nutrition. The company will consider using its Kikuchi Research Center in Kikuchi City, Kumamoto Prefecture, and its Koshi Plant in Koshi City, Kumamoto Prefecture, which are capable of producing vaccines for 57 million new influenza cases. (Photo taken on May 25, 2020, location unknown, credit: Nikkan Kogyo Shimbun / Kyodo News Images)